High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cells.


ImmunoRNases represent a highly attractive alternative to conventional immunotoxins for cancer therapy. Quantitative production of immunoRNases in appropriate expression systems, however, remains a major challenge for further clinical development of these novel compounds. Here we describe a method for high-level production and purification of a fully… (More)
DOI: 10.1007/978-1-59745-554-1_24


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics